Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273761 | 1.00 | SLC2A1 (0.69) | SLC2A1KCNH2 | |
| SCHEMBL4273771 | 1.00 | SLC2A1 (0.69) | SLC2A1KCNH2 | |
| SCHEMBL27579662 | 0.89 | KCNH2 (0.65) | SLC2A1KCNH2 | |
| SCHEMBL4272906 | 0.89 | KCNH2 (0.65) | SLC2A1KCNH2 | |
| SCHEMBL4276734 | 0.86 | KCNH2 (0.65) | SLC2A1KCNH2 | |
| SCHEMBL4276747 | 0.86 | KCNH2 (0.65) | SLC2A1KCNH2 | |
| SCHEMBL4276754 | 0.86 | KCNH2 (0.65) | SLC2A1KCNH2 | |
| SCHEMBL7017868 | 0.83 | KCNH2 (0.65) | SLC2A1KCNH2 | |
| SCHEMBL4269202 | 0.83 | KCNH2 (0.65) | SLC2A1KCNH2 | |
| SCHEMBL4278299 | 0.82 | SLC2A1 (0.99) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | claimed |
| US-6962917-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-11-08 | — | — | US | claimed |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | claimed |
| EP-1305308-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| WO-2002008224-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-01-31 | — | — | WO | claimed |
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | disclosed |
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. | 2006-01-19 | — | — | US | disclosed |
| US-6962917-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-11-08 | — | — | US | disclosed |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | AZI2, AMPD2, AMPD1 | SLC2A1 3639/4885KCNH2 1010/4885 |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | AZI2, NPEPPS, AMPD2 | SLC2A1 3675/4885KCNH2 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.